摘要：晚期食管癌系统治疗方案-V2版NCCN指南解读（-05-15）
正文：
晚期食管癌系统治疗方案-V2版NCCN指南解读
★一、一线方案
aAnFDA-approvedbiosimilarisanappropriatesubstitutefortrastuzumab.
bLeucovorinisindicatedwithcertainfluorouracil-basedregimens.Dependingonavailability,theseregimensmaybeusedwithorwithoutleucovorin.Forimportant
informationregardingtheleucovorinshortage,pleaseseetheDiscussion.
hIfnopriortumorprogressionwhileontherapywithacheckpointinhibitor.
iCapecitabinecannotbeusedinterchangeablywithfluorouracilinregimenscontainingirinotecan.
★二、二线方案
bLeucovorinisindicatedwithcertainfluorouracil-basedregimens.Dependingonavailability,theseregimensmaybeusedwithorwithoutleucovorin.Forimportant
informationregardingtheleucovorinshortage,pleaseseetheDiscussion.
eSeeNCCNGuidelinesforManagementofImmunotherapy-RelatedToxicities.
hIfnopriortumorprogressionwhileontherapywithacheckpointinhibitor.
iCapecitabinecannotbeusedinterchangeablywithfluorouracilinregimenscontainingirinotecan.
jPembrolizumabisFDA-approvedforthethird-linetreatmentofpatientswithEGJadenocarcinomawithPD-L1expressionlevelsbyCPSof≥1,asdeterminedby
anFDA-approved